A halo of IL-10 kept implanted insulin cells working past 100 days

Rice University bioengineers packed cells engineered to secrete interleukin 10 into the same hydrogel capsules as insulin-producing pancreatic beta cells, and reported on 5 August 2026 that the implants held blood glucose under control in diabetic mice for more than 100 days — close to five times longer than beta cells implanted without the protection. The work appears in Science Advances, with Omid Veiseh as corresponding author and Dilrasbonu Vohidova, Boram Kim and Amanda Nash as co-first authors.

The problem being solved is scar tissue. An implanted capsule reads as foreign, the body walls it off in fibrosis, and the cells inside starve behind the wall. The standard answer is to suppress the whole immune system, which trades diabetes for infection and cancer risk. Here the IL-10 stays local — a chemical halo a few cell-widths across rather than a body-wide drug. In nonhuman primates the implants kept producing IL-10 with no signs of harm elsewhere.

This is preclinical work in mice and monkeys, not people. What it changes is the shape of the bet: an encapsulated islet transplant that does not need lifelong immunosuppression is a different product from one that does.